Since 2014, there has been an expansion of approved pharmaceutical options for irritable bowel syndrome (IBS) patients including newly approved drug treatment options.
Join lead authors, Drs. Lin Chang and Anthony Lembo, at DDW® 2022 as they share key highlights and takeaways from the upcoming two-part guidelines: Pharmacological Management of IBS-C and Pharmacological Management of IBS-D and how these new guidelines will affect clinical practice. Both guidelines will be published in the July issue of Gastroenterology.
Session: 2022 AGA Guideline Highlights: Pharmacological Management of IBS, Pharmacological Management of Weight Loss Interventions in the Management of Obesity, and Systemic Therapy for Hepatocellular Carcinoma (HCC)
Date/time: Saturday, May 21, 8-9:30 a.m. PDT
Location: Room 29AB at the San Diego Convention Center (SDCC).
